Quality‐of‐life evaluations in children and adolescents with Ewing sarcoma treated with pencil‐beam‐scanning proton therapy
Damien C. Weber(University Hospital of Geneva), Gabriele Calaminus(University Hospital Bonn), C. Teske(University Hospital Münster), Jürgen Beer(University of Bern), Barbara Bachtiary(Paul Scherrer Institute), Beate Timmermann(Essen University Hospital), Katja Baust(University Hospital Bonn), Ulrike Kliebsch(Paul Scherrer Institute), Alessia Pica(University of Lausanne), M. Walser(Paul Scherrer Institute)
Cited by 5
Related Papers
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419